Mangoceuticals, Inc.
MGRX
$1.73
-$0.07-3.89%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 511.10K | 615.90K | 755.10K | 866.90K | 844.90K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 511.10K | 615.90K | 755.10K | 866.90K | 844.90K |
| Cost of Revenue | 216.40K | 235.90K | 312.60K | 362.50K | 323.20K |
| Gross Profit | 294.70K | 380.00K | 442.50K | 504.40K | 521.70K |
| SG&A Expenses | 8.78M | 7.66M | 8.30M | 8.40M | 8.65M |
| Depreciation & Amortization | 721.50K | 721.50K | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.96M | 8.86M | 8.85M | 9.01M | 9.06M |
| Operating Income | -9.45M | -8.24M | -8.10M | -8.14M | -8.21M |
| Income Before Tax | -11.18M | -8.71M | -9.33M | -9.13M | -9.02M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.18 | -8.71 | -9.33 | -9.13 | -9.02 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 1.10K | 1.00K | 800.00 | 300.00 | 0.00 |
| Net Income | -11.18M | -8.71M | -9.33M | -9.13M | -9.02M |
| EBIT | -9.45M | -8.24M | -8.10M | -8.14M | -8.21M |
| EBITDA | -8.31M | -7.51M | -8.08M | -8.12M | -8.19M |
| EPS Basic | -4.50 | -4.95 | -5.83 | -6.53 | -7.33 |
| Normalized Basic EPS | -2.60 | -2.88 | -3.64 | -4.08 | -4.58 |
| EPS Diluted | -4.50 | -4.95 | -5.83 | -6.53 | -7.33 |
| Normalized Diluted EPS | -2.60 | -2.88 | -3.64 | -4.08 | -4.58 |
| Average Basic Shares Outstanding | 10.97M | 7.95M | 6.64M | 5.69M | 5.00M |
| Average Diluted Shares Outstanding | 10.97M | 7.95M | 6.64M | 5.69M | 5.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |